M
Maryline Barrie
Researcher at Aix-Marseille University
Publications - 62
Citations - 2841
Maryline Barrie is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Temozolomide & Bevacizumab. The author has an hindex of 22, co-authored 58 publications receiving 2480 citations. Previous affiliations of Maryline Barrie include French Institute of Health and Medical Research & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Radiotherapy for glioblastoma in the elderly.
Florence Keime-Guibert,Olivier Chinot,Luc Taillandier,Stéphanie Cartalat-Carel,Marc Frenay,Guy Kantor,Jean-Sébastien Guillamo,Eric Jadaud,Philippe Colin,Pierre-Yves Bondiau,Philippe Menei,Hugues Loiseau,Valérie Bernier,Jérôme Honnorat,Maryline Barrie,Karima Mokhtari,Jean-Jacques Mazeron,Anne Bissery,Jean-Yves Delattre +18 more
TL;DR: Radiotherapy results in a modest improvement in survival, without reducing the quality of life or cognition, in elderly patients with glioblastoma.
Journal ArticleDOI
Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide
Olivier Chinot,Maryline Barrie,Stéphane Fuentes,N. Eudes,Sophie Lancelot,Philippe Metellus,Xavier Muracciole,Diane Braguer,L'Houcine Ouafik,Pierre-Marie Martin,Henry Dufour,Dominique Figarella-Branger +11 more
TL;DR: This dose-dense temozolomide regimen resulted in modest antitumor activity with an acceptable safety profile in the neoadjuvant setting, and expression of MGMT correlated with response to temozalomide.
Journal ArticleDOI
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
Jaime Gállego Pérez-Larraya,François Ducray,Olivier Chinot,Isabelle Catry-Thomas,Luc Taillandier,Jean-Sébastien Guillamo,Chantal Campello,Annick Monjour,Stéphanie Cartalat-Carel,Maryline Barrie,Aymeri Huchet,Patrick Beauchesne,Mona Matta,Karima Mokhtari,Marie-Laure Tanguy,Jérôme Honnorat,Jean-Yves Delattre +16 more
TL;DR: Temozolomide is associated with improvement of functional status in 33% of patients and appears to increase survival compared with supportive care alone, especially in patients with methylated MGMT promoter.
Journal ArticleDOI
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Alexandre Carpentier,Philippe Metellus,Renata Ursu,Sarah Zohar,Francois Lafitte,Maryline Barrie,Yuxia Meng,Margaretha Richard,Christophe Parizot,Florence Laigle-Donadey,Guy Gorochov,Dimitri Psimaras,Marc Sanson,Annick Tibi,Olivier Chinot,Antoine F. Carpentier +15 more
TL;DR: Despite a few cases showing a radiological response, CpG-28 showed modest activity on the 6-month PFS in this patient population, and the molecular or clinical characteristics of a subgroup of patients that could potentially benefit from such an approach remain to be defined.
Journal ArticleDOI
Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy
Oliver-Louis Chinot,Stéphane Honoré,Henry Dufour,Maryline Barrie,Dominique Figarella-Branger,Xavier Muracciole,Diane Braguer,Pierre-Marie Martin,François Grisoli +8 more
TL;DR: Temozolomide is safe and effective in the treatment of recurrent anaplastic oligodendroglioma and AOA and correlated with improved survival.